Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Direct factor Xa (FXa) inhibitors are increasingly prescribed for outpatients, and those transitioning to unfractionated heparin (UFH) for hospital admission are monitored via an anti-FXa assay. Because of assay interference, UFH results would often be critically elevated, confounding dosing.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Thromb Haemost

Title: Journal of thrombosis and haemostasis : JTH

Publisher: Wiley

ISSN (Electronic): 1538-7836

ISSN (Print): 1538-7836

Publication date (Electronic): July 2020

Volume: 18

Issue: 7

Affiliations

[1 ] Special Coagulation Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

[2 ] College of Pharmacy, University of Michigan Medical School, Ann Arbor, MI, USA.

[3 ] Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA.

Article

DOI: 10.1111/jth.14806

PubMed ID: 32216028

SO-VID: 51badf4f-e2ac-4c54-b935-7d1fc4ea7e9a

History

Keywords: apixaban,drug monitoring,factor IIa,heparin,rivaroxaban

Data availability:

Keywords: apixaban, drug monitoring, factor IIa, heparin, rivaroxaban

Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.

Read this article at

Abstract

Related collections

Anti-Trafficking Review

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 169

Cited by 2